Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Vaccine

• Publication date

  2011-02-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2010.12.116PMID 21219979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

  2010cited by this paper
• Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

  2010cited by this paper
• Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

  2010cited by this paper
• Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.

  2010cited by this paper
• Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza

  2010cited by this paper
• Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

  2010cited by this paper
• Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

  2010cited by this paper
• Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.

  2010cited by this paper
• Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

  2010cited by this paper
• Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

  2010cited by this paper
• Update: influenza activity--United States, April-August 2009.

  2009cited by this paper
• Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  2009cited by this paper
• New influenza A (H1N1) virus: global epidemiological situation, June 2009.

  2009cited by this paper
• Pandemic influenza in a southern hemisphere setting: the experience in Peru from May to September, 2009.

  2009cited by this paper
• Update: influenza activity - United States, August 30-October 31, 2009.

  2009cited by this paper
• A novel influenza A (H1N1) vaccine in various age groups.

  2009cited by this paper
• Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  2009cited by this paper
• The safety and immunogenicity of influenza vaccine in children with asthma in Mexico.

  2009cited by this paper
• Australia's winter with the 2009 pandemic influenza A (H1N1) virus.

  2009cited by this paper

• Active pharmacovigilance of the seasonal trivalent influenza vaccine produced by Instituto Butantan: A prospective cohort study of five target groups.

  2021influential citation
• Partnering with parents to remove barriers and improve influenza immunization rates for young children

  2020cites this paper
• Vaccines for preventing influenza in healthy children.

  2018cites this paper
• واکسنها برای پیشگیری از وقوع آنفلوآنزا در کودکان سالم

  2018cites this paper
• H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines

  2017cites this paper
• Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.

  2017cites this paper
• Prevention and Control of Seasonal Influenza with Vaccines.

  2016cites this paper
• Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.

  2015cites this paper
• Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals

  2015cites this paper
• Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season

  2015cites this paper
• Caracterização fenotípica e funcional da resposta imune de voluntários imunizados contra influenza A (H1N1)pdm09

  2015cites this paper
• Influenza and Parainfluenza Viral Infections in Children

  2014cites this paper
• Safety of Vaccines Used for Routine Immunization in the United States.

  2014cites this paper
• Influenza and parainfluenza viral infections in children.

  2014cites this paper
• Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.

  2013cites this paper
• Aptamer–Nanomaterial Conjugates for Medical Applications

  2013cites this paper
• Studying use and risks of medicines in children: a European approach

  2013cites this paper
• Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees

  2013cites this paper
• Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

  2013cites this paper
• Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.

  2013cites this paper
• A Novel Synthetic Receptor-Based Immunoassay for Influenza Vaccine Quantification

  2013cites this paper
• A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.

  2012cites this paper
• Vaccines for preventing influenza in healthy children.

  2012cites this paper
• Evaluations for In Vitro Correlates of Immunogenicity of Inactivated Influenza A H5, H7 and H9 Vaccines in Humans

  2012influential citation
• Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6–35 months: a randomized, double‐blind, controlled phase I clinical trial

  2012cites this paper
• Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age

  2012cites this paper
• Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to One Year After Immunization with a Pandemic A/H1N1 Influenza Vaccine in Children 3 to < 9 Years of Age.

  2012cites this paper
• Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

  2012cites this paper
• Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

  2012cites this paper
• afety of pandemic H 1 N 1 vaccines in children and adolescents

  2011cites this paper
• Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.

  2011cites this paper
• Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

  2011cites this paper
• Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

  2011influential citation
• Safety of pandemic H1N1 vaccines in children and adolescents.

  2011cites this paper
• Immunogenicity and Reactogenicity of 2009 Influenza A (H1N1) Inactivated Monovalent Non-Adjuvanted Vaccine in Elderly and Immunocompromised Patients

  2011cites this paper
• Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France

  2011cites this paper
• The vaccination policy and the Code of Practice of the Joint Committee on Vaccination and Immunisation (JCVI): are they at odds?

  2011cites this paper